ClinicalTrials.gg
Not yet recruitingNCT07766889Updated Aug 17, 2026

Neoadjuvant Presurgical Becotatug Vedotin (MRG003) Plus Pucotenlimab (HX008) in Oral Cavity Squamous Cell Carcinoma

A Phase 2 interventional study of Becotatug Vedotin (MRG003) and Pucotenlimab in Oral Squamous Cell Carcinoma, Head and Neck Cancer and Locally Advanced Head and Neck Cancer, sponsored by Sun Yat-sen University. Not yet recruiting at 2 sites in China. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-08-17.

Sponsored by Sun Yat-sen University · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
32
Allocation
Not applicable
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 16 studies testing becotatug vedotin in Squamous Cell Carcinoma of Head and Neck — 15 open to participants now, 15 under way, 2 of them phase 3. becotatug vedotin · Squamous Cell Carcinoma of Head and Neck.

Planned enrollment
13th of 16
32 · median 52
Started
2026
with 11 others
Phase 2
13 of 16
12 open now
Primary completion
2027-06
later than 3 of 14 live
Registered
14th of 16
by date
Lead sponsor
4 of 16
Sun Yat-sen University

Among the 16 studies testing becotatug vedotin in Squamous Cell Carcinoma of Head and Neck, this one is the 13th largest by planned enrollment, is one of 12 that started in 2026, is one of 13 in phase 2, reaches primary completion later than 3 of the 14 other live ones, and was the 14th registered.

Squamous Cell Carcinoma of Head and Neck

2,019 studies on the registry are indexed under Squamous Cell Carcinoma of Head and Neck; 573 are open to participants now.

Browse Squamous Cell Carcinoma of Head and Neck studies →

Open to participants now

15 of the 16 studies testing becotatug vedotin in Squamous Cell Carcinoma of Head and Neck are open now, in 1 country. Recruiting first, the newest first:

9 more — sign in →

By country, each count listing its studies:

All 15 open studies →

Where they have run

About becotatug vedotin

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 435 Squamous Cell Carcinoma of Head and Neck studies recruiting now, 311 (71%) set no upper age limit and 87 (20%) stop at 75 or younger; 5 take children under 18; 13 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies testing becotatug vedotin in Squamous Cell Carcinoma of Head and Neck, or all of them as a file.
02

Study summary

This is a phase 2, open-label, single-arm clinical trial evaluating neoadjuvant therapy with Becotatug vedotin (MRG003) combined with Pucotenlimab (HX008) in patients with previously untreated, resectable stage III-IVA oral cavity squamous cell carcinoma (OSCC) with a PD-L1 Combined Positive Score (CPS) of 1 or higher.

Eligible participants will receive 3 cycles of neoadjuvant treatment (Becotatug vedotin 2.3 mg/kg plus Pucotenlimab 200 mg, intravenously, every 3 weeks), followed by radical surgery 2-3 weeks after the last cycle of neoadjuvant therapy. Postoperative adjuvant radiotherapy will be stratified based on pathological response and risk factors: patients achieving major pathological response (MPR, defined as ≤10% residual viable tumor) with negative margins and no extranodal extension (ENE) will receive de-escalated radiotherapy (50-54 Gy); patients not achieving MPR or with high-risk features will receive standard radiotherapy (60-66 Gy) with or without concurrent cisplatin chemotherapy.

The primary endpoint is major pathological response (MPR). Secondary endpoints include objective response rate (ORR), pathological complete response (pCR), event-free survival (EFS), overall survival (OS), and safety profile. Exploratory biomarkers will be assessed in tumor tissue and peripheral blood.

A total of 32-33 participants will be enrolled using a Simon two-stage optimal design (α=0.05, power=80%).

Read the detailed description

Oral cavity squamous cell carcinoma (OSCC) accounts for approximately 42.5% of all head and neck cancers, with about 60% of patients presenting with locally advanced disease (stage III-IVA). Despite standard-of-care treatment consisting of radical surgery followed by radiotherapy or concurrent chemoradiotherapy, the 5-year overall survival rate remains below 50%, and approximately one-third of patients experience disease recurrence within one year.

The 2025 NCCN Guidelines recommend perioperative immune checkpoint inhibitor therapy for locally advanced OSCC patients with PD-L1 CPS ≥1, based on the results of the KEYNOTE-689 trial. However, neoadjuvant pembrolizumab monotherapy has demonstrated limited pathological responses, with pCR and MPR rates of only 3.0% and 9.8%, respectively. Combining immune checkpoint inhibitors with other therapeutic modalities has emerged as a promising strategy to enhance pathological response rates.

Becotatug vedotin (MRG003) is a novel anti-EGFR antibody-drug conjugate (ADC) that delivers the potent cytotoxic agent monomethyl auristatin E (MMAE) specifically to EGFR-expressing tumor cells. In a phase II study, MRG003 monotherapy achieved an objective response rate of 43% in patients with recurrent/metastatic HNSCC who had failed prior platinum-based chemotherapy and PD-1/L1 inhibitors, representing one of the highest ORRs reported for ADC monotherapy in HNSCC.

Pucotenlimab (HX008) is a humanized anti-PD-1 monoclonal antibody with an Fc-engineered modification that enhances binding affinity to the neonatal Fc receptor (FcRn), potentially extending serum half-life and providing more sustained PD-1 pathway blockade. It has demonstrated robust antitumor activity across multiple tumor types, with an ORR of 49.0% in MSI-H/dMMR solid tumors.

Preclinical and clinical evidence supports the synergistic mechanism of combining an EGFR-targeted ADC with a PD-1 inhibitor: ADC-mediated tumor cell killing promotes antigen release and T-cell infiltration, while PD-1 blockade reverses T-cell exhaustion, creating a "pro-immune activation and de-immunosuppression" synergistic effect. In a phase Ib/II study of this combination in recurrent/metastatic HNSCC, the ORR reached 60.0% with a manageable safety profile, providing the rationale for moving this combination forward to the neoadjuvant setting.

Study Design:

This is a multicenter, open-label, single-arm phase II trial. The study will enroll 32-33 patients with previously untreated, resectable stage III-IVA OSCC with PD-L1 CPS ≥1. The trial employs a Simon two-stage optimal design with the null hypothesis that the MPR rate is ≤10% and the alternative hypothesis that the MPR rate is ≥30%, with a one-sided alpha of 0.05 and 80% power.

Treatment Regimen:

Neoadjuvant phase: 3 cycles of Becotatug vedotin 2.3 mg/kg plus Pucotenlimab 200 mg, IV, Q3W Surgery: Radical tumor resection and neck dissection, performed 2-3 weeks after the last neoadjuvant cycle

Adjuvant phase (stratified by pathological response):

Group A (de-escalation layer): MPR (≤10% residual viable tumor) with negative margins and ENE-negative → de-escalated radiotherapy (50-54 Gy) Group B (standard layer): Not achieving MPR or presence of high-risk factors → standard radiotherapy (60-66 Gy) ± concurrent cisplatin chemotherapy

Study Endpoints:

Primary: Major pathological response (MPR) rate Secondary: ORR, pCR, pPR, EFS, OS, DCR, DoR, DFFS, LRFFS, safety/tolerability, and quality of life (EORTC QLQ-C30/H\&N43, PRO-CTCAE) Exploratory: Dynamic changes in the tumor immune microenvironment, predictive value of PD-L1 and EGFR expression, and peripheral blood immune biomarkers

Sample Size:

Based on Simon's two-stage optimal design: 10 patients in stage I; if ≤1 response is observed, the trial will be terminated for futility; otherwise, an additional 19 patients will be enrolled, totaling 29 patients. Allowing for a 10% dropout rate, the sample size is expanded to 32-33 patients.

03

Conditions studied

  • Oral Squamous Cell Carcinoma
  • Head and Neck Cancer
  • Locally Advanced Head and Neck Cancer
  • Neoadjuvant Therapy

Keywords

  • MRG003, Becotatug vedotin, Pucotenlimab, anti-PD-1, ADC, EGFR, neoadjuvant therapy, oral squamous cell carcinoma, OSCC, head and neck cancer
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Voluntary participation with written , good compliance, and willingness to complete follow-up.
  • Age ≥18 years and ≤70 years, regardless of gender.
  • performance status score of 0 or 1.
  • Histopathologically confirmed, previously untreated, primary oral cavity squamous cell carcinoma (OSCC); central laboratory-confirmed Combined Positive Score (CPS) ≥1; clinical stage III-IVA (AJCC 8th edition) with potential for curative surgical resection as assessed by the investigator; no evidence of definite locoregional residual or distant .
  • Adequate organ function within 14 days prior to the first dose, without transfusion or hematopoietic growth factor support:
  • Bone marrow: ≥1.5×10\^9/L; count ≥100×10\^9/L; ≥90 g/L.
  • Liver: ≤1.5×; /ALT ≤3.0×ULN; ALP ≤2.5×ULN; serum albumin ≥28 g/L.
  • Kidney: (Ccr) ≥40 mL/min (calculated by Cockcroft-Gault formula) or serum creatinine ≤1.5×ULN.
  • Coagulation: ≤1.5×ULN and APTT ≤1.5×ULN (excluding patients receiving therapeutic anticoagulation).
  • Cardiac: ≥50% with no significant cardiac dysfunction.
  • Negative serum pregnancy test within 7 days prior to the first dose for women of ; all fertile male and female participants must agree to use highly effective from signing of informed consent through 1 year after the last dose of Pucotenlimab.

Exclusion criteria

Exclusion Criteria:

  • Age >70 years or \<18 years.
  • History of other within the past 5 years, except adequately treated basal cell carcinoma, squamous cell carcinoma of the skin, or carcinoma in situ of the cervix.
  • infection.
  • positive with HBV DNA >200 IU/mL or 1000 copies/mL.
  • antibody positive.
  • Severe concurrent diseases that may pose significant risks or affect trial compliance, including unstable cardiac disease, renal disease, chronic hepatitis, poorly controlled diabetes (fasting blood glucose >1.5×), severe cognitive impairment, or psychiatric disorders.
  • Active pulmonary tuberculosis infection within the past 1 year, or history of active tuberculosis >1 year ago unless documented prior standard anti-tuberculosis treatment.
  • History of interstitial lung disease.
  • Active, known, or suspected disease. Exceptions: type I diabetes, hypothyroidism requiring only hormone replacement therapy, and skin conditions not requiring systemic treatment (e.g., vitiligo, psoriasis, alopecia).
  • Systemic (>10 mg/day prednisone equivalent) or other therapy within 28 days prior to signing . Patients receiving ≤10 mg/day prednisone equivalent or inhaled/topical corticosteroids are eligible.
  • within 30 days prior to signing informed consent or planned during the study.
  • Prior surgery, chemotherapy, radiotherapy, immunotherapy, or other anti-tumor therapy for head and neck cancer (excluding diagnostic procedures).
  • Known to macromolecular protein preparations, or any component of Becotatug vedotin, Pucotenlimab, or cisplatin.
  • Pregnancy, lactation, or anticipated pregnancy during the study period.
Terms in these criteria, in plain language(24)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
32 participants (estimated)

Study arms

  • Experimental
    Neoadjuvant MRG003 + Pucotenlimab

    Participants receive 3 cycles of neoadjuvant Becotatug vedotin (MRG003) 2.3 mg/kg plus Pucotenlimab (HX008) 200 mg intravenously every 3 weeks, followed by radical surgery 2-3 weeks after the last neoadjuvant cycle. Postoperative adjuvant radiotherapy is stratified based on pathological response and risk factors.

    Drug: Becotatug Vedotin (MRG003) · Drug: Pucotenlimab

Interventions

  • Anti-EGFR antibody-drug conjugate (ADC) composed of a recombinant humanized anti-EGFR monoclonal antibody conjugated to monomethyl auristatin E (MMAE) via a cleavable valine-citrulline linker. Administered at 2.3 mg/kg intravenously every 3 weeks for 3 cycles.

    Also known as: MRG003

  • Humanized anti-PD-1 monoclonal antibody (IgG4) that blocks the interaction between PD-1 and its ligands PD-L1 and PD-L2. Administered at 200 mg intravenously every 3 weeks for 3 cycles.

    Also known as: HX008

06

What researchers measure

Primary outcomes

  1. Major Pathological Response (MPR) Rate

    MPR is defined as the proportion of participants with ≤10% residual viable tumor cells in the resected primary tumor specimen following neoadjuvant therapy, as assessed by central pathology review.

    Time frame: At the time of surgery, following 3 cycles of neoadjuvant therapy (each cycle is 21 days)

Secondary outcomes

  1. Objective Response Rate (ORR)

    Proportion of participants achieving complete response (CR) or partial response (PR) based on RECIST 1.1 criteria, assessed by imaging (MRI/CT) after completion of 3 cycles of neoadjuvant therapy.

    Time frame: At the end of Cycle 3 (each cycle is 21 days), prior to surgery

  2. Pathological Complete Response (pCR) Rate

    Proportion of participants with no residual viable tumor cells in the resected primary tumor specimen and regional lymph nodes following neoadjuvant therapy, as assessed by central pathology review.

    Time frame: At the time of surgery, following 3 cycles of neoadjuvant therapy (each cycle is 21 days)

  3. Pathological Partial Response (pPR) Rate

    Proportion of participants with significant reduction of residual viable tumor cells in the resected primary tumor specimen following neoadjuvant therapy, but not meeting the criteria for MPR or pCR, as assessed by central pathology review.

    Time frame: At the time of surgery, following 3 cycles of neoadjuvant therapy (each cycle is 21 days)

  4. Event-Free Survival (EFS)

    Time from treatment initiation to the first occurrence of any of the following events: disease progression precluding surgery, local or distant recurrence, or death from any cause.

    Time frame: Up to 5 years

  5. Overall Survival (OS)

    Time from treatment initiation to death from any cause.

    Time frame: Up to 5 years

  6. Disease Control Rate (DCR)

    Proportion of participants achieving complete response (CR), partial response (PR), or stable disease (SD) based on RECIST 1.1 criteria.

    Time frame: At the end of Cycle 3 (each cycle is 21 days), prior to surgery

  7. Duration of Response (DoR)

    Time from first documented complete response (CR) or partial response (PR) to disease progression or death from any cause.

    Time frame: Up to 5 years

  8. Distant Failure-Free Survival (DFFS)

    Time from treatment initiation to the occurrence of distant metastasis.

    Time frame: Up to 5 years

  9. Locoregional Failure-Free Survival (LRFFS)

    Time from treatment initiation to first locoregional treatment failure (local primary or cervical lymph node recurrence).

    Time frame: Up to 5 years

  10. Acute and Late Adverse Event Profile

    Acute toxicity assessed by NCI-CTCAE version 5.0, including hematologic and non-hematologic toxicities. Late radiation toxicity assessed by RTOG/EORTC criteria, including skin, subcutaneous tissue, mucosa, salivary glands, spinal cord, brain, eye, larynx, pharynx, esophagus, bone, and joint.

    Time frame: From signing of informed consent through 30 days after last dose of study treatment for acute toxicity; long-term follow-up for late toxicity

  11. Change in EORTC QLQ-C30 Quality of Life Scores

    Change from baseline in quality of life scores assessed by the EORTC QLQ-C30 (version 3.0) questionnaire.

    Time frame: Baseline, at the end of Cycle 3 (each cycle is 21 days), post-surgery, at 1 month post-treatment, and annually up to 5 years post-treatment.

  12. Change in EORTC QLQ-H&N43 Quality of Life Scores

    Change from baseline in quality of life scores assessed by the EORTC QLQ-H\&N43 questionnaire.

    Time frame: Baseline, at the end of Cycle 3 (each cycle is 21 days), post-surgery, at 1 month post-treatment, and annually up to 5 years post-treatment.

  13. Change in PRO-CTCAE Symptom Severity Scores

    Change from baseline in patient-reported symptom and side effect severity assessed by the NCI PRO-CTCAE (version 1.0) questionnaire.

    Time frame: Baseline, at the end of Cycle 3 (each cycle is 21 days), post-surgery, at 1 month post-treatment, and annually up to 5 years post-treatment.

07

Study locations

2 sites
08

References and documents

Individual participant data

Plan to share: No — This is a single-arm phase II exploratory study with a small sample size (32 participants). The primary objective is to evaluate the efficacy and safety of a novel neoadjuvant combination therapy. IPD sharing is not planned as the data are not sufficient to support generalized conclusions and contain sensitive information that may compromise participant confidentiality. Data sharing is not required by the sponsor or regulatory authorities for this early-phase study.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Sep 2026; primary completion for Jun 2027, 9 months later.

Of 298 non-industry phase 2 interventional studies under Squamous Cell Carcinoma of Head and Neck, half reached primary completion within 56 months of starting (the median), counting those still running; a quarter within 37 and three quarters within 85. This study's planned 9 months is below that.

Counting every sponsor, half of 366 studies reached it within 53 months; a quarter within 35 and three quarters within 82.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 6, 2026
First posted
Aug 17, 2026
StartEst.
Sep 1, 2026
Primary completionEst.
Jun 30, 2027
CompletionEst.
Dec 31, 2028
Last update
Aug 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07766889
Collaborators
Lepu Biopharma Co., Ltd.
Responsible party
Mao Yanping (Mao Yanping, Professor, Department of Radiation Oncology, Sun Yat-sen University Cancer Center, Sun Yat-sen University) — Principal investigator
First posted
Aug 17, 2026
Start date
Sep 1, 2026 (estimated)
Primary completion
Jun 30, 2027 (estimated)
Completion
Dec 31, 2028 (estimated)
Last update
Aug 17, 2026

Study contacts

Yanping Mao
Contact
maoyp5@mail.sysu.edu.cn
+86-13500019575
Yanfeng Chen
Contact
chyanf@mail.sysu.edu.cn

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Becotatug vedotin · Pucotenlimab

Start the discussion